Search alternatives:
significantly teer » significantly better (Expand Search), significantly weaker (Expand Search), significantly lower (Expand Search)
point decrease » point increase (Expand Search)
onto decrease » nn decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
Showing 121 - 140 results of 1,780 for search '(( significantly ((onto decrease) OR (point decrease)) ) OR ( significantly teer decrease ))', query time: 0.46s Refine Results
  1. 121
    DIO Mice Liver Staining.

    DIO Mice Liver Staining. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 122
    Trends of peroxisome-related gene expression in liver tissue.

    Trends of peroxisome-related gene expression in liver tissue. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 123
    NAS (NAFLD Activity Score) of liver tissue of mice in each group after 8 weeks of treatment with either vehicle (V) or Kylo-0603 (0.1-10 mg/kg/day).

    NAS (NAFLD Activity Score) of liver tissue of mice in each group after 8 weeks of treatment with either vehicle (V) or Kylo-0603 (0.1-10 mg/kg/day). by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 124
    The body weight and cholesterol levels of the mice were recorded before the administration of the drug.

    The body weight and cholesterol levels of the mice were recorded before the administration of the drug. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 125
    Effect of Kylo-0603 drug on the reversal of steatosis and inhibition of fibrotic process in liver tissues of the MASH mouse models (F2 ~ 3), analyzed by SHG/TPEF microscopy combined with digital image analysis technique.

    Effect of Kylo-0603 drug on the reversal of steatosis and inhibition of fibrotic process in liver tissues of the MASH mouse models (F2 ~ 3), analyzed by SHG/TPEF microscopy combine... by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 126
    The structures of T3 and Kylo-0603.

    The structures of T3 and Kylo-0603. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 127
    Synthesis process of Kylo-0603.

    Synthesis process of Kylo-0603. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 128
    ESI-HRMS spectra for Kylo-0603.

    ESI-HRMS spectra for Kylo-0603. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 129
    General procedure for the synthesis of Kylo-0603.

    General procedure for the synthesis of Kylo-0603. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 130
    Post-mortem lesions of chickens with decreased egg production in Yancheng in 2023.

    Post-mortem lesions of chickens with decreased egg production in Yancheng in 2023. by Yan Wang (15435)

    Published 2025
    Save to List
    Saved in:
  11. 131
    Consecutive time points of data collection.

    Consecutive time points of data collection. by Martin Matzka (2636344)

    Published 2025
    “…Effect sizes expectedly decreased over time. Physical quality of life remained relatively constant over time and was the only outcome for which social integration on admission was not a significant prognostic factor.…”
    Save to List
    Saved in:
  12. 132
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 133
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 134
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 135
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 136
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 137
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 138
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 139
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 140
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: